REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Radionuclide Or Intended Radionuclide Containing; Adjuvant Or Carrier Compositions; Intermediate Or Preparatory Compositions > Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Attached To Antibody Or Antibody Fragment Or Immunoglobulin; DerivativeAttached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.08/16/07 - 20070189964 - Cytotoxicity mediation of cells evidencing surface expression of cd44 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic ... 08/16/07 - 20070189963 - Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis The present invention relates to antibodies with sub-nanomolar affinity specific for a characteristic epitope of the ED-B domain of fibronectin, a marker of angiogenesis Furthermore, it relates to the use of radiolabeled high affinity anti ED-B antibodies for detecting new-forming blood vessels in vivo and a diagnostic kit comprising comprising ... 08/16/07 - 20070189962 - Mutated anti-cd22 antibodies and immunoconjugates Recombinant immunotoxins are fusion proteins composed of the Fv domains of antibodies fused to bacterial or plant toxins. RFB4 (Fv)-PE38 is an immunotoxin that targets CD22 expressed on B cells and B cell malignancies. The present invention provides antibodies and antibody fragments that have improved ability to bind the CD22 ... 08/09/07 - 20070183971 - Immunoconjugates targeting syndecan-1 expressing cells and use thereof Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part ... 08/09/07 - 20070183970 - Chimeric, human and humanized anti-granulocyte antibodies and methods of use The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocyte related disorders and diseases, such as leukemia. ... 07/26/07 - 20070172423 - Composition and method for modulating vasculogenesis for angiogenesis A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the ... 07/12/07 - 20070160531 - Targeting endothelium for tissue-specific delivery of agents Mechanisms and routes by which molecules can be delivered into cells, particularly endothelial cells, through the action of caveolae, G domains and other plasma membrane domains and components, are described, as are delivery systems comprising antibodies to caveolar proteins or receptors and also agents conjugated to the antibody or ligand, ... 07/12/07 - 20070160530 - Antibodies and molecules derived therefrom that bind to steap-1 proteins Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits issue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The ... 07/12/07 - 20070160529 - Radioimmunoconjugates for targeted alpha therapy A radioimmunoconjugate for targeted alpha therapy comprises an alpha-emitter (e.g. Bi-213) linked to the monoclonal antibody C595. This radioimmunoconjugate is widely applicable in cancer therapy and is particularly efficient for treatment of pancreatic and prostate cancer, as well as for breast and ovarian cancer. ... 07/12/07 - 20070160528 - Method to evaluate the likelehood of development of bone metastasis based on the determination of calcium binding proteins This invention provides methods to determine which patients with cancer will develop bone metastasis by determining the presence or levels of calcium binding proteins in the blood or other tissues of these patients. These calcium binding proteins include MRP14. In addition, this invention provides methods for treating patients with cancer ... 06/28/07 - 20070148089 - Novel serpentine transmembrane antigens expressed in human cancers and uses thereof Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four ... 06/21/07 - 20070140966 - Multivalent immunoglobulin-based bioactive assemblies The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Preferred embodiments concern hexameric stably tethered structures comprising one or more IgG antibody fragments and which may be monospecific or bispecific. The disclosed methods and compositions provide a ... 06/21/07 - 20070140965 - Methods to ameliorate and image angioplasty-induced vascular injury Methods for inhibiting restenosis in blood vessels expanded by angioplasty are described. The method comprises administering blood vessel wall-targeted emulsion containing an anti-restenotic agent. ... 06/21/07 - 20070140964 - Cytokine receptor zcytor17 multimers Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and ... 06/21/07 - 20070140963 - Cytokine receptor zcytor17 multimers Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and ... 06/14/07 - 20070134154 - Tumor-targeted nanodelivery systems to improve early mri detection of cancer The present invention is in the fields of drug delivery, cancer treatment and diagnosis and pharmaceuticals. This invention provides a method of making antibody- or antibody fragment-targeted immunoliposomes for the systemic delivery of molecules to treat and image diseases, including cancerous tumors. The invention also provides immunoliposomes and compositions, as ... 06/07/07 - 20070128112 - Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy ... 06/07/07 - 20070128111 - Methods and compositions for increasing antibody production The invention provides methods and compositions for improved expression and production of recombinant antibodies in host cell expression systems. In particular, prokaryotic expression and production of antibodies with modified hinge cysteine residues are provided. The invention further provides compositions, kits and articles of manufacture for practicing methods of the present ... 05/17/07 - 20070110668 - Modulation of immunity and ceacam1 activity The present technology comprises methods for regulating an the immune system, and in particular methods for the regulation of a specific immune response, including the regulation of lymphocyte activity. Methods of the present technology comprise both the negative and positive modulation of CEACAM1 protein function. ... 05/10/07 - 20070104647 - Ovr115 antibody compositions and methods of use The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr115) antibodies that bind to Ovr115 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Ovr115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect ... 05/03/07 - 20070098634 - Compositions and methods for the diagnosis and treatment of tumor The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. ... 05/03/07 - 20070098633 - Virtual colonoscopy with radiolabeled phospholipid ether analogs The present invention provides agents and methods for dual modality virtual colonoscopy that gives both anatomical and functional information using hybrid CT/PET scanning. In preferred embodiments, the present invention provides radiolabeled tumor-specific agents and methods for distinguishing benign polyps from malignant tumors. In further embodiments, the present invention provides compositions ... 04/26/07 - 20070092443 - Antibodies that recognize hyperproliferative cells and methods of making and using same The invention relates to antibodies that bind to antigens, such as antigens associated with hyperproliferating cells, and methods of treating hyperproliferative disorders. The invention antibodies are useful for treating hyperproliferative disorders, such as neoplasia. ... 04/19/07 - 20070086944 - Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic applications The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes. ... 04/19/07 - 20070086943 - Epha2 agonistic monoclonal antibodies and methods of use thereof The present invention relates to methods and compositions designed for the treatment, management, or prevention of cancer, particularly, metastatic cancer. The methods of the invention comprise the administration of an effective amount of one or more antibodies that bind to and agonize EphA2, thereby increasing EphA2 phosphorylation and decreasing EphA2 ... 04/19/07 - 20070086942 - Methods and compositions for generating bioactive assemblies of increased complexity and uses The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) ... 04/12/07 - 20070081942 - Gene differentially expressed in breast and bladder cancer, and encoded polypeptides The present invention is directed to antibodies or antigen binding fragments thereof that specifically bind to the cancer specific antigen, C35. This invention also relates to a polynucleotide encoding the antibody or antigen binding fragment thereof as well as vectors and host cells comprising the polynucleotide. The present invention further ... 04/05/07 - 20070077199 - Humanized collagen antibodies and related methods The invention provides an antibody, or functional fragment thereof, a grafted antibody, or functional fragment thereof, comprising one or more complementarity determining regions (CDRs) having at least one amino acid substitution in one or more CDRs of a heavy chain CDR, where the antibody or functional fragment thereof has specific ... 03/29/07 - 20070071676 - Methods and therapies for treating inflammatory conditions with exposed collagen Compositions and methods for treating and imaging vulnerable plaque and other inflammatory conditions in a patient rely on the delivery of conversion electron-emitting sources and other radionuclides to regions of exposed collagen in the vasculature or other body lumens. The conversion electron-emitting sources or other radionuclides are coupled to a ... 03/29/07 - 20070071675 - Dual variable domain immunoglobulin and uses thereof The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases. ... 03/29/07 - 20070071674 - Polynucleotides encoding novel isoforms of igsf9 Human IGSF9 and LIV-1 polypeptides and DNA (RNA) encoding such polypeptides are disclosed. The disclosed polypeptides and/or polynucleotide are particularly useful generating antibodies, both modified and native, which bind IGSF9 or LIV-1. Also disclosed are pharmaceutical compositions and vaccines comprising the antibodies, polypeptides and polynucleotides of the invention. Also disclosed ... 03/22/07 - 20070065361 - Ligands to radiation-induced molecules A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor ... 03/15/07 - 20070059241 - Neutralizing human anti-igfr antibody The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention. ... 03/15/07 - 20070059240 - Method for diagnosis of chronic allograft rejection The present invention provides a method for the diagnosis of chronic rejection in allografts. The method comprises identification of tertiary lymphoid organs (TLO) in the transplanted organs as a marker of chronic rejection by immunohistochemical detection for the presence of specific TLO antigens in biopsy samples or by radiographic imaging ... 03/08/07 - 20070053836 - Cytotoxicity mediation of cells evidencing surface expression of cd44 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB) or derivatives thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the ... 03/08/07 - 20070053835 - Compositions and methods for the diagnosis and treatment of tumor The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. ... 03/01/07 - 20070048223 - Cytokine receptor zcytor17 multimers Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and ... 03/01/07 - 20070048222 - Cytokine receptor zcytor17 multimers Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and ... 03/01/07 - 20070048221 - Antibodies that bind both bcma and taci Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane ... 03/01/07 - 20070048220 - Antibodies that bind both bcma and taci Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane ... 03/01/07 - 20070048219 - Antibody fragment-polymer conjugates and uses of same Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also ... 03/01/07 - 20070048218 - Compositions and methods for the diagnosis and treatment of tumor The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. ... 03/01/07 - 20070048217 - F-18 peptides for pre targeted positron emission tomography imaging F-18 radiolabeled peptides are prepared by reacting a peptide comprising a hydroxylamine, a thiosemicarbazide, a hydrazine or a free amine group with 4-[18F]Fluorobenzaledyde. Specific, non-limiting examples of F-18 radiolabeled peptides are described herein. The labeled peptides are useful, for example, in clinical positron emission tomography. ... 02/22/07 - 20070041901 - Stabilized aptamers to psma and their use as prostate cancer therapeutics The present invention provides stabilized, high affinity nucleic acid ligands to PSMA. Methods for the identification and preparation of novel, stable, high affinity ligands to PSMA using the SELEX™ method with 2′-O-methyl substituted nucleic acids, and cell surface SELEX™ are described herein. Also included are methods and compositions for the ... 02/15/07 - 20070036719 - Prostate cancer diagnosis and treatment The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, ... 02/08/07 - 20070031331 - Treatment of disorders The present invention concerns treatment of polychondritis or mononeuritis multiplex in a mammal with an effective amount of an antibody that binds to CD20, optionally also with another agent that treats such disorders in an effective amount. ... 02/08/07 - 20070031330 - Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can ... 02/08/07 - 20070031329 - Method of obtaining gallium-68 and use thereof and device for carrying out said method The present invention relates to a method of obtaining from a 68Ge/68Ga generator and a method of producing 68Ga-radiolabelled complexes using the obtained 68Ga. The invention further relates to a kit, which could be used to obtain 68Ga and a kit, which could be used for the production of 68Ga-radiolabelled ... 02/01/07 - 20070025915 - Determination of am-binding proteins and the association of adrenomedullin (am) therewith The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the ... 02/01/07 - 20070025914 - Bronchioalveolar stem cells and uses thereof The present invention features stems cells from lungs, methods of isolating such stem cells, methods of diagnosing lung diseases, and method of treating lung diseases, including cancer, chronic obstructive pulmonary disease, cystic fibrosis, and emphysema. ... 02/01/07 - 20070025913 - Imaging, diagnosis and treatment of disease The present invention relates to endothelial cell-specific genes and encoded polypeptides and materials and uses thereof in the imaging, diagnosis and treatment of conditions involving the vascular endothelium. ... 02/01/07 - 20070025912 - Cytotoxicity mediation of cells evidencing surface expression of cd63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The ... 02/01/07 - 20070025911 - Cancer specific monoclonal antibodies Novel monoclonal antibodies and binding fragments thereof specific to human breast cancer, lung cancer, colon cancer and other cancers. The monoclonal antibody does not bind to the cell surface of normal human tissues. The corresponding cancer-specific antigen or antigens with an apparent molecular weight of 40-52 130-200 kDa and polynucleotides ... 01/25/07 - 20070020179 - Acute leukemia and lymphoblastic lymphoma-specific cd43 epitope and use thereof The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells, ... 01/18/07 - 20070014725 - Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for nmr diagnosis and radiodiagnosis as well as radiotherapy The invention relates to conjugates that consist of macrocyclic metal complexes with biomolecules and their production. The conjugates are suitable as contrast media in NMR diagnosis and radiodiagnosis as well as as agents for radiotherapy. High relaxivity is achieved by a special liganding of macrocyclic compounds, and a fine-tuning of ... 01/18/07 - 20070014724 - Interferon alpha antibodies and their uses The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules ... 01/11/07 - 20070009434 - Imaging and therapeutic method using monocytes wherein the group Ab comprises a ligand that binds to monocytes, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering monocyte function, and when the conjugate is being used for diagnosing the ... 01/11/07 - 20070009433 - 14094, a novel human trypsin family member and uses thereof The invention provides isolated nucleic acids molecules, designated 14094 nucleic acid molecules, which encode a novel trypsin family member. Elevated expression of 14094 mRNA was detected in breast, ovarian, lung, and liver cancers compared to normal cells derived from these tissues. The invention also provides antisense nucleic acid molecules, recombinant ... 12/28/06 - 20060292074 - Tomoregulin antibodies and uses thereof The present invention relates to antibodies, and antigen-binding antibody fragments, directed against a Tomoregulin (TR) polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications. ... 12/21/06 - 20060286031 - Modulators of tissue regeneration Proteins which are upregulated in injured or regenerating tissues, as well as the DNA encoding these proteins, are disclosed, as well as therapeutic compositions and methods of treatment encompassing these compounds. ... 12/21/06 - 20060286030 - Anti-cd71 monoclonal antibodies and uses thereof for treating malignant tumor cells The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumor cells, especially metastatic cutaneous and uveal melanoma cells. ... 12/14/06 - 20060280680 - Hybrid nanocrystals for treatment and bioimaging of disease Hybrid nanocrystals able to reach specific targets in the body for treatment and biological imaging are provided, as well as methods of making and administering same for treatment of disease conditions and for bioimaging and radiotherapy. The hybrid nanocrystals and methods can be used alone or in combination with other ... 12/14/06 - 20060280679 - Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells Antibodies to antigen presenting cells may be utilized to interfere with the interaction of the antigen presenting cell and immune cells, including T cells. Peptides may be linked to said antibodies thereby generating an immune response to such peptides. Preferably peptides linked to the antibodies are associated with autoimmunity. ... 12/07/06 - 20060275212 - Treatment and diagnosis of cancer The present invention is directed to the use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen. These biological agents can be labeled and used ... 12/07/06 - 20060275211 - Antibodies and related molecules that bind to 161p2f10b proteins Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B ... 12/07/06 - 20060275210 - Antibodies that specifically bind to chemokine beta-4 The present invention relates to antibodies and related molecules that specifically bind to CK-B4. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including cancers, as well as immune system diseases and disorders including autoimmune diseases, inflammatory disorders, ... 11/23/06 - 20060263293 - Click chemistry method for synthesizing molecular imaging probes The present disclosure provides a method for preparing a radioactive ligand or radioactive substrate having affinity for a target biomacromolecule, the method comprising: (a) reacting a first compound comprising a first functional group capable of participating in a click chemistry reaction, with a radioactive reagent under conditions sufficient to displace ... 11/16/06 - 20060257317 - Combination therapy in the treatment of cancer Disclosed herein is a method of treating a tumor by administering to the subject a treatment effective amount of a therapeutic antibody and an alkylating agent. ... 11/09/06 - 20060251580 - Lectin conjugates A conjugate includes at least one target-seeking unit, which specifically binds to receptors on the surface of endothelial cells, and at least one effector unit which is coupled to the unit by a linker. The effector unit exhibits at least one signal unit and optionally at least one therapeutic active ... 11/09/06 - 20060251579 - Medicament for the two-step perioperative therapy of solid tumours The present invention describes the use of an agent endowed with tumour tropism in combination with another agent with anticancer activity and with an affinity for the first agent for the preparation of a medicament useful for the two-step perioperative therapy of solid tumours. The advantages of the present invention ... 11/02/06 - 20060246004 - Antibody variants and uses thereof The invention provides improved humanized CD20 binding antibodies for treatment of B cell malignancies and autoimmune diseases. ... 10/26/06 - 20060239912 - Carrier molecules The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even ... 10/26/06 - 20060239911 - Antibodies with immune effector activity and that internalize in endosialin-positive cells This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic ... 10/26/06 - 20060239910 - Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific ... 10/26/06 - 20060239909 - Treatment of protein degradation disorders The invention relates to methods of treating protein degradation disorders, such cellular proliferative disorders (e.g., cancer) and protein deposition disorders (e.g., neurodegenerative disorders). The invention provides methods and pharmaceutical compositions for treating these diseases using aggresome inhibitors or combinations of aggresome inhibitors and proteasome inhibitors. The invention further relates to ... 10/19/06 - 20060233705 - Diagnosis by determination of hyperactivity or increased expression of members of cell signaling pathways A non-invasive method for determining the presence or severity of a bodily disorder associated with hyperactivity or increased expression of a signal transduction protein, transcription factor, or protein kinase that is a member of the MAPK or GPCR pathways. A reagent that binds to such a signal transduction protein, transcription ... 10/19/06 - 20060233704 - Prochelator for the preparation of radiometal labeled molecules having improved biological properties Chelating compounds for labeling bioactive molecules with a radiometal, having general formula (I) in which: both Y groups may be positioned either trans as shown or cis; A is an effector molecule, such as a peptide, in particular octreotide, CCK, substance P, gastrine, a protein, in particular an antibody or ... 10/12/06 - 20060228300 - Stably tethered structures of defined compositions with multiple functions or binding specificities The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an ... 10/12/06 - 20060228299 - Constructs binding to phosphatidylserine and their use in disease treatment Disclosed are new phosphatidylserine binding constructs with surprising combinations of properties, and a range of diagnostic and therapeutic conjugates thereof. The new constructs effectively bind phosphatidylserine targets in disease and enhance their destruction, and can also specifically deliver attached imaging or therapeutic agents to the disease site. Also disclosed are ... 10/05/06 - 20060222588 - Antilymphoma targeting agents with effector and affinity functions linked by a trifunctional reagent A medical agent comprising a reagent conjugated to an anti-lymphoma antibody is disclosed, as well as a kit containing said medical agent, use of said medical agent, and a method for treatment of lymphoma. The reagent may comprise an effector, e.g. an antitumor agent or a diagnostic marker, and an ... 09/28/06 - 20060216236 - Methods of inhibiting alphavbeta3-mediated angiogenesis and tumor development The invention provides methods for identifying genes and proteins modulated by an antagonist of αvβ3 that inhibits binding of αvβ3 to an ECM component. It additionally provides methods for using the products of the identified genes, or for using the identified proteins, for inhibiting angiogenesis, tumor metastasis, and other tumor ... 09/28/06 - 20060216235 - Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can ... 09/28/06 - 20060216234 - Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can ... 09/28/06 - 20060216233 - Cytotoxicity mediation of cells evidencing surface expression of cd44 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The ... 09/28/06 - 20060216232 - Compositions and methods for the treatment of tumor of hematopoietic origin The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. ... 09/28/06 - 20060216231 - Methods for diagnosing and treating tumors and suppressing cd promoters Methods of treating tumors, reducing white blood cell numbers, and inhibiting CD promoters are provided. ... 09/21/06 - 20060210475 - Humanized l243 antibodies Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapuetic and diagnostic, as well as research-related uses for such antibodies, are provided. ... 09/21/06 - 20060210474 - Cytotoxicity mediation of cells evidencing surface expression of cd63 This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The ... 09/21/06 - 20060210473 - Vegf-conjugate combined methods for tumor vasculature targeting and tumor treatment The present invention relates generally to methods and compositions for targeting the vasculature of solid tumors using immunological- and growth factor-based reagents. In particular aspects, antibodies carrying diagnostic or therapeutic agents are targeted to the vasculature of solid tumor masses through recognition of tumor vasculature-associated antigens, such as, for example, ... 09/14/06 - 20060204435 - Detection, imaging, and depletion of intracellular pathogens Methods and compositions are disclosed for detecting and depleting cells infected with bacteria of the Chlamydiaceae family from a biological sample. Compositions include, for example, an immunoglobulin constant region polypeptide linked to an imaging moiety or a bactericide. Methods include, for example, contacting a biological sample that includes chlamydia infected ... 09/07/06 - 20060198784 - Methods of treatment using antibodies to neutrokine-alpha The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV ... 08/31/06 - 20060193772 - Drugs for treating cancer The invention aims to provide a medicament for treating cancer in which a cancer therapeutic effect is synergistically increased using a substance inhibiting activities of insulin-like growth factor-I (IGF-I) and insulin-like growth factor-II (IGF-II). According to the invention, there are provided a medicament for treating cancer which comprises a substance ... 08/31/06 - 20060193771 - Anti-cd30 stalk and anti-cd30 antibodies suitable for use in immunotoxins CD30 is a receptor expressed on cells of Hodgkin's disease and certain leukemias. The extracellular portion of CD30 is cleaved, releasing a form known as sCD30. The invention relates in part to the discovery that a residual, extracellular “stalk” of CD30 remains after cleavage of sCD30. The stalk provides an ... 08/31/06 - 20060193770 - Method of determining cytokine dosage for myelosuppressive state The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective ... 08/24/06 - 20060188440 - Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer Compositions and methods for detecting and treating cancers expressing Mullerian inhibiting substance Type II receptor (MISIIR) are provided. ... 08/24/06 - 20060188439 - Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetection The current invention relates to the development and methods of use of a recombinant agonistic antibody anti-human CD137, and glycosylation variants thereof. These antibodies act as anti-cancer agents and/or immune modulators that are effective in shrinking solid tumors or other cancerous indications and preventing their recurrence. The types of cancer ... 08/17/06 - 20060182683 - Methods for reduced renal uptake of protein conjugates Kidney uptake of antibody fragment conjugates and protein conjugates in patients is reduced by administration to the patient of one or more compounds selected from the group consisting of D-lysine, poly-D-lysine, or poly-L-lysine, or pharmaceutically acceptable salts or carboxyl derivatives thereof. ... 08/17/06 - 20060182682 - Diagnosis of prostate cancer Methods for diagnosing prostate cancer, and differentiate prostate cancer from other prostate complications, and use of said method, and diagnosing and monitoring lymph gland metastasis, post operative examinations, and examinations during or after radiation, cytostatic, and androgen treatments are disclosed. The methods comprise injecting tracer-labelled PSA or hK2 specific antibodies, ... 08/03/06 - 20060171884 - Binding proteins specific for human matriptase Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses ... 08/03/06 - 20060171883 - Detection, localization and staging of tumors using labeled activated lymphocytes directed to a tumor specific epitope A Disclosed are methods for detecting and localizing a cell-specific antigen in a mammal, such as a human subject, comprising exposing peripheral blood mononuclear cells (PBMCs) of the mammal to an immunogenic peptide epitope of the antigen, under conditions for antigen-specific activation of T lymphocytes in the PBMCs, thereby producing ... 07/27/06 - 20060165592 - Nk cell receptor conjugates for treating malignancies The present invention relates generally to compositions useful in therapies involving the selective destruction of tumor cells in vivo. In particular, this invention relates to a conjugate which comprises a target recognition segment and an active cytotoxic segment. The target recognition segment comprises a receptor specific to NK cells, wherein ... 07/13/06 - 20060153770 - Method of treating tumors A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); ... 07/06/06 - 20060147375 - Antibodies and related molecules that bind to psca proteins CROSS-REFERENCE TO RELATED APPLICATIONS ... 07/06/06 - 20060147374 - Compositions and methods for the diagnosis and treatment of tumor The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. ... 07/06/06 - 20060147373 - Compositions and methods for the diagnosis and treatment of tumor The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. ... 07/06/06 - 20060147372 - Dna encoding mck-10, a novel receptor tyrosine kinase The present invention relates to the novel family of receptor tyrosine kinases, herein referred to as MCK-10, to nucleotide sequences and expression vectors encoding MCK-10, and to methods of inhibiting MCK-10 activity. The invention relates to differentially spliced isoforms of MCK-10 and to other members of the MCK-10 receptor tyrosine ... 06/29/06 - 20060140857 - Method of the administration of drugs with binding affinity for plasma protein and preparation to be used in the method A method of the administration of drugs with binding affinity for plasma protein and drugs regulating the effective ingredient dose of drugs with binding affinity for plasma protein; and a preparation whereby the effective ingredient dose of drugs with binding affinity for plasma protein is regulated. The above administration method ... 06/22/06 - 20060133995 - Method for determining suitability of various contrast agents for the imaging examination of the patient and uses of the ligand contained in a selected contrast agent A method is for determining suitability of various contrast agents for the imaging examination of the. In this case, a tissue sample is taken from the patient, it is divided into a plurality of individual samples and a contrast agent which binds to a particular target structure in the tissue ... 06/22/06 - 20060133994 - Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis The present invention relates to antibodies with sub-nanomolar affinity specific for a characteristic epitope of the ED-B domain of fibronectin, a marker of angiogenesis. Furthermore, it relates to the use of radiolabelled high affinity anti ED-B antibodies for detecting new-forming blood vessels in vivo and a diagnostic kit comprising comprising ... 06/15/06 - 20060127311 - Radiation dosimetry and blocking antibodies and methods and uses therefor in the treatment of cancer Disclosed is a method for dosimetry estimation for a region of interest at or around a surgically created resection cavity in a subject. These methods enable medical practitioners to estimate the amount of administered Radioimmunotherapy (RIT) agent needed to safely and effectively achieve a final Radiation Absorbed Dose (RAD). Furthermore, ... 06/15/06 - 20060127310 - Amplification of biotin-mediated targeting The present invention relates to the delivery of drug, peptide and protein pharmaceuticals using a biotin-mediated uptake system. More particularly the invention relates to the amplification of active substance delivery with the biotin uptake system using a biotin-active substance-polymer conjugate or a biotin-nanoparticle conjugate. The invention also relates to processes ... 06/08/06 - 20060120959 - Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof The invention provides chemical conjugates between an immunoglobulin Fab fragment and molecular entities imparting diagnostic or therapeutic utility, whereby the only sites of conjugation on the Fab fragment are one or both of the sulfhydryl groups deriving from the selective and quantitative reduction of the inter-chain disulfide bond of said ... 06/01/06 - 20060115428 - Identification and characterization of function-blocking anti-ed-b-fibronectin antibodies The invention relates to recombinant polypeptides, in particular antibodies or antibody fragments that bind Ed-B-isoforms of fibronectin and can block their function. In addition, the diagnostic and pharmaceutical application of the polypeptides according to the invention is disclosed. ... 05/25/06 - 20060110324 - Human anti-epidermal growth factor receptor single-chain antibodies Human anti-epidermal growth factor receptor (EGFR) single-chain antibodies (scFvs) were isolated from a human IgM phage display library using purified epidermal growth factor receptor as antigen. Two isolates with different amino acid sequences were identified by ELISA as epidermal growth factor receptor-specific. The scFvs bind to the full length epidermal ... 05/18/06 - 20060104899 - Production and use of novel peptide-based agents for use with bi-specific antibodies The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a linker moiety. The linker moiety encompasses a hapten to which antibodies have been prepared. The antigenic ... 05/18/06 - 20060104898 - Ligands to radiation-induced molecules A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor ... 05/11/06 - 20060099144 - Tumor association of mdl-1 and methods The invention provides methods for detecting, diagnosing, localizing and imaging tumors. The invention also relates to methods for detecting, diagnosing, localizing, imaging and treating cancer. ... 05/11/06 - 20060099143 - Antibodies binding to human magic roundabout (mr), polypeptides and uses thereof for inhibition angiogenesis A method of inhibiting angiogenesis in an individual in need thereof comprising administering an antibody that selectively binds to the extracellular region of human magic roundabout (MR) to the individual. An antibody that has the amino acid sequences i) to iii), the amino acid sequences iv) to vi), or the ... 05/11/06 - 20060099142 - Cancer associated araf1 protein kinase and its uses Detection of expression of the provided protein kinase in cancers is useful as a diagnostic, for determining the effectiveness of drugs, and determining patient prognosis. The encoded polypeptides further provides a target for screening pharmaceutical agents effective in inhibiting the growth or metastasis of tumor cells. The present invention further ... 05/04/06 - 20060093553 - Cd26-based therapies for cancers and immune disease Therapeutic methods comprising administering a composition comprising CD26 thereof in conjunction with chemotherapeutic agents or radiotherapeutic agents for the prevention and treatment of cancers are provided. Also provided are methods for potentiating immune responses comprising administering a composition comprising CD26. ... 04/27/06 - 20060088471 - Compounds for enzyme inhibition Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the ... 04/20/06 - 20060083683 - Antibody fragment-polymer conjugates and uses of same Described are conjugates formed by an antibody fragment covalently attached to a non-proteinaceous polymer, wherein the apparent size of the conjugate is at least about 500 kD. The conjugates exhibit substantially improved half-life, mean residence time, and/or clearance rate in circulation as compared to the underivatized parental antibody fragment. Also ... 03/30/06 - 20060067885 - Method and kit for imaging and treating organs and tissues Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically ... 03/30/06 - 20060067884 - Method for radiolabeling antibodies with yttrium-90 Methods and kits for radiolabeling proteins, peptides and ligands with radiolytic isotopes, particularly yttrium-90, are disclosed, whereby sufficient purity, specific activity and binding affinity are achieved such that the radiolabeled protein may be directly administered to a patient without further column purification. Such kits and methods will be particularly useful ... 03/23/06 - 20060062729 - Enhanced ligand binding to neurotensin receptors Provided are combinations and methods for enhancing ligand binding to neurotensin receptor (NTR). Such combinations and methods are useful for applications such as (a) assessing NTR expression, NTR coupling, and NTR function in vitro, (b) assessing NTR expression or NTR function in vivo, (c) imaging tumors; and (d) targeting therapeutics ... 03/23/06 - 20060062728 - Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using A multifunctional cross-bridged tetraaza macrocyclic compound has at least one side arm that comprises a moiety that is capable of forming a bond with another molecule, which has a targeting moiety that directs the compound to a site a marker substance. The compound is chelated to a medically active material ... 03/16/06 - 20060057062 - Compositions and methods useful in pretargeted imaging Disclosed are multispecific macromolecular constructs, blocking agents and radiolabeled effector molecules, as well as kits and methods for imaging tissue of interest in a mammalian subject. The multispecific macromolecular construct is capable of binding a radiolabeled effector molecule that can be imaged, as well as a disease marker such as ... 03/09/06 - 20060051292 - Novel self-assembly molecules There is provided a method of forming a multimeric complex having affinity for a target. The method comprises: obtaining a plurality of self-assembly molecules, said self-assembly molecules including complementary self-assembly units such as verotoxin subunit B, each of which is operatively connected to an interaction domain such as a single ... 02/23/06 - 20060039859 - Blood brain barrier permeation peptides Novel blood-brain barrier permeant amyloid-targeting peptides and peptide conjugates are described. The peptide conjugates include a radioisotope or other label in a stable complex that translocates across brain capillary endothelial cell monolayers. The labeled peptide conjugate binds to amyloid plaques (Aβ) associated with Alzheimer's disease, and is useful for the ... 02/23/06 - 20060039858 - Radiolabeled antibodies and peptides for treatment of tumors This invention provides methods for imaging and/or treating a tumor in a subject which comprise administering to the subject an amount of a radiolabeled antibody and/or peptide effective to image and/or treat the tumor, where the radiolabeled antibody and/or peptide binds to a cellular component released by dying tumor cells. ... 02/23/06 - 20060039857 - Methods for diagnosis using anti-cytokine receptor antibodies Labeled antibodies, antibody fragments or peptides binding to soluble cytokines or cytokine receptors are used to diagnose whether a patient has cancer or an autoimmune disease. In a preferred embodiment, a radiolabelled tag that is chemically bound to a peptide, antibody, or antibody fragment specific for sTNFR-1 and/or sTNFR2 is ... 02/16/06 - 20060034759 - Production and use of novel peptide-based agents with bispecific antibodies The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable ... 02/09/06 - 20060029543 - Treatment of b-cell lymphoma A method of treating B-cell lymphoma comprises administering to a patient a chemotherapeutic regimen, followed by treatment with a radiolabeled anti-CD20 antibody, wherein at the time of said treatment with said radiolabeled antibody said patient is not refractory to said chemotherapeutic regimen and has not relapsed. ... 02/02/06 - 20060024232 - Imaging and therapeutic agents targeting proteins expressed on endothelial cell surface Methods of delivering an agent in a tissue-specific manner, by targeting proteins expressed on endothelial cell surface, are described. The methods can be used for detecting, imaging and/or treating neoplasia, angiogenesis or neovasculature, as well as for diagnostics and methods of assessing treatment efficacy. ... 02/02/06 - 20060024231 - Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface Methods of delivering an agent in a tissue-specific manner, particularly lung tissue, by targeting a protein expressed on the endothelial cell surface, are described. The methods can be used for detecting, imaging and/or treating pathologies, as well as for diagnostics. ... 02/02/06 - 20060024230 - Customized therapeutics and in situ diagnostics Customized therapeutics and in situ diagnostics for patient therapy and diagnosis takes advantage of tools including techniques for derivatizing colloids with self-assembled monolayers. This provides the capability of a wide variety of assays including chemical or biochemical agent/agent interaction studies. Bio-derivatized colloids, with or without signaling entities, are used to ... 01/26/06 - 20060018829 - Cellular receptors utilized as carrier agents for pharmaceutical compounds used in tumor imaging and cancer treatment A method whereby non-immunogenic intraspecies proteins are used as carrier compounds to deliver imaging agents and pharmaceutical drugs to tumors in the human patient. This invention describes the propensity of certain solubilized cellular receptor proteins to localize in necrotic or inflamed areas of tumors but not in healthy normal tissues. ... 01/19/06 - 20060013767 - Virtual colonoscopy with radiolabeled phospholipid ether analogs The present invention provides agents and methods for dual modality virtual colonoscopy that gives both anatomical and functional information using hybrid CT/PET scanning. In preferred embodiments, the present invention provides radiolabeled tumor-specific agents and methods for distinguishing benign polyps from malignant tumors. In further embodiments, the present invention provides compositions ... 01/12/06 - 20060008415 - Stable liquid and lyophilized formulation of proteins The present invention is directed to stable protein derivatives, e.g., antibodies, antibody fragments or peptides, with at least one free thiol group coupled to N-acetyl-L-cysteine, N-ethyl-maleimide, or cysteine and the methods of making such derivatives. In addition, stable liquid pharmaceutical formulations comprising such proteins or their derivatives and stable lyophilized ... 01/05/06 - 20060002855 - Targeted combination immunotherapy of cancer and infectious diseases The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present ... 01/05/06 - 20060002854 - Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies The present invention provides a conjugate that contains a therapeutic moiety linked to a homing peptide or peptidomimetic which selectively homes to vasculature of pre-malignant dysplastic skin and which includes the amino acid sequence SRPRR (SEQ ID NO: 1) or a conservative variant or peptidomimetic thereof. The present invention further ... 12/29/05 - 20050287066 - Anti-rat angiotensin i-converting enzyme (ace, cd143) monoclonal antibodies and uses thereof It was demonstrated previously that mAb 9B9 to ACE accumulated selectively in the rat lung after systemic injection and thus could be used as a powerful tool for immunotargeting therapeutic agents/genes to the lung microvasculature. The current invention generated novel set of monoclonal antibodies (mAbs) to rat ACE in order ... 12/15/05 - 20050276756 - Compositions as adjuvants to improve immune responses to vaccines and methods of use The invention provides compositions containing an antigen and a TIM targeting molecule. The invention additionally provides a TIM targeting molecule conjugate, for example, a TIM targeting molecule targeted to a therapeutic or diagnostic moiety. The invention additionally provides methods of using such compositions. In one embodiment, the invention provides a ... 12/01/05 - 20050265924 - Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer A gene (designated 161P2F10B) and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or ... 11/24/05 - 20050260133 - Strategy for designing patient-specific anti-cancer drugs A diagnostic technique for matching anti-cancer peptide drugs to the molecular profiles of individual cancer tumors, and a method using the technique for a patient-specific treatment of tumors in mammals. This strategy matches anti-cancer peptide drugs to the molecular profiles of individual tumors, and includes the development of two banks, ... 11/24/05 - 20050260132 - Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta The present invention relates to a method of inhibiting growth of tumor cells which overexpress a receptor protein tyrosine phosphatase zeta (PTPζ) by treatment of the cells with antibodies which recognize PTPζ and/or inhibit PTPζ function. The present invention also provides compounds and pharmaceutically acceptable compositions for administration in the ... 11/24/05 - 20050260131 - Pharmaceuticals for enhanced delivery to disease targets Pharmaceuticals for enhanced delivery to a disease target comprises a pair of compounds. The first compound comprises a first oligopeptide conjugated to a first moiety for coupling with a diagnostic or therapeutic active agent. The second compound comprises a second oligopeptide conjugated to a targeting species having a targeting moiety ... 11/17/05 - 20050255042 - On-demand cleavable linkers for radioconjugates for cancer imaging and therapy The present invention provides compositions comprising a biological agent, a targeting moiety, and a peptide linker attaching the biological agent to the targeting moiety, wherein the peptide linker is selectively cleaved by a protease. Efficient methods are provided for administering the compositions of the present invention for treating cancer or ... 11/17/05 - 20050255041 - Cancerous disease modifying antibodies The present invention relates to a method for producing patient cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can ... 11/03/05 - 20050244333 - Humanized anti-cea t84.66 antibody and uses thereof Embodiments of the present invention utilize a more efficient CDR grafting technique to generate humanized versions of the T84.66 antibody. The technique used to generate these antibodies utilizes crystallographic structural data to select an immunoglobulin framework having maximum structural overlap with a non-human donor molecule. This technique was used to ... 10/27/05 - 20050238578 - High dose radionuclide complexes for bone marrow suppression The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such ... 10/13/05 - 20050226812 - Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins Certain cells, including various types of cancer cells, express KIRHy proteins. Targeting using KIRHy polypeptides, nucleic acids encoding for KIRHy polypeptides and anti-KIRHy antibodies provides a method of killing or inhibiting that growth of cancer cells that express the KIRHy protein. Methods of therapy and diagnosis of disorders associated with ... 10/06/05 - 20050220705 - Methods for treating non-melanoma cancers with paba The present invention relates to a method for treating non-melanotic cancers by administration of PABA. The present invention also relates to the potentiation of standard cancer treatment of radiation, radioimmunotherapy, and/or chemotherapy using PABA. ... 09/29/05 - 20050214212 - Antibodies specific for cd44v6 The present invention belongs to the field of oncology. The invention relates to antibodies with specified sequence which are specific for an epitope which is coded by the variant exon v6 of the CD44 gene and to derivatives of said antibody. The invention also provides nucleic acid molecules encoding said ... 09/29/05 - 20050214211 - Nucleic acid and corresponding protein entitled 121p2a3 useful in treatment and detection of cancer A novel gene (designated 121P2A3) and its encoded protein, and variants thereof, are described wherein 121P2A3 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 121P2A3 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 121P2A3 gene ... 09/29/05 - 20050214210 - Antibodies that immunospecifically bind to trail receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these ... 09/29/05 - 20050214209 - Antibodies that immunospecifically bind to trail receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these ... 09/29/05 - 20050214208 - Antibodies that immunospecifically bind to trail receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR7. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR7 antibodies, vectors and host cells containing these ... 09/29/05 - 20050214207 - Antibodies that immunospecifically bind totrail receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR7. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR7 antibodies, vectors and host cells containing these ... 09/29/05 - 20050214206 - Antibodies that immunospecifically bind to trail receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR7. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR7 antibodies, vectors and host cells containing these ... 09/29/05 - 20050214205 - Antibodies that immunospecifically bind to trail receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR7. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR7 antibodies, vectors and host cells containing these ... 09/22/05 - 20050207977 - Multimeric protein engineering The invention described herein encompasses (1) artificial preproproteins and the polynucleotides encoding them, (2) methods for producing these biomolecules, and (3) methods for their use. The artificial preproproteins of this invention comprise a protein assembly capable of producing a multimeric protein from a single protein. FIG. 4 illustrates generally the ... 09/22/05 - 20050207976 - High energy phototherapeutic agents A high energy phototherapeutic agents or radiosensitizer agent comprised of a halogenated xanthene, or an agent that exhibits a preference for concentration in biologically sensitive structures in diseased tissue, and methods of treating and imaging using radiosensitizer agents in diseased tissue. ... 09/22/05 - 20050207975 - Method for treating malignancy and autoimmune disorders in humans The present invention relates to a method for treating malignancy and autoimmune disorders and for preventing allograft rejection. Conjugated or unconjugated monoclonal anti-Tac antibodies are employed to treat the above conditions. Clinical therapies have been designed to treat immune diseases and lymphomas in patients using conjugated anti-Tac antibodies. ... 09/22/05 - 20050207974 - Endothelial cell markers and related reagents and methods of use thereof The present invention provides polynucleotides and polypeptides (VECSM polynucleotides and polypeptides) that are differentially expressed in vascular endothelial cells. The invention further provides a variety of compositions, diagnostic, and therapeutic methods based on identification of these markers. In particular, the invention provides a targeting agent linked to a functional moiety, ... 09/15/05 - 20050201932 - Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof The invention provides compositions and methods for specific binding to a region of the polymeric immunoglobulin receptor (pIgR) of a cell with the provisos that the ligand does not substantially bind to the most abundant form of the secretory component (SC) of pIgR present in an organ of interest of ... 09/15/05 - 20050201931 - Lat1 transporters expressed in blood brain barrier cells LAT1 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the LAT1 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in ... 09/01/05 - 20050191239 - Method for preparing conjugates of proteins and chelating agents Improved synthesis methods are provided for preparing conjugates of proteins and chelating agents. In the synthesis methods, non-stable bonds are hydrolyzed after the conjugate is synthesized, for example by treating the conjugate with a quenching agent. The synthesis method provides conjugates that are substantially free of non-stable bonds between the ... 08/25/05 - 20050186136 - Soluble jam-1, 2, and 3 as diagnostic & prognostic markers in cardiovascular, vascular, and inflammatory disorders This invention pertains to methods and composition of novel assays for the measurements of soluble JAM-1, 2, and 3 in body fluids for the diagnosis and therapeutic of various pathological disorders involved in cardiovascular, vascular, inflammatory, and angiogenesis-mediated disorders (cancer, ocular, inflammatory disorders). Additionally, these novel assays can be used ... 08/04/05 - 20050169838 - Radiolabeling method Antibody binding assays and radiolabeling kits are disclosed for radiolabeling and testing therapeutic antibodies in the commercial setting. In particular, the kits are designed for making and evaluating radiolabeled anti-CD20 conjugates to be used for the treatment and imaging of B cell lymphoma tumors. All kit reagents are sterile and ... 07/28/05 - 20050163709 - Development of dna probes and immunological reagents specific for cell surface-expressed molecules and transformation-associated genes This invention provides a method for preparing a hybridoma cell line which produces an antibody capable of specifically binding to a cell surface-expressed protein which expresses on the surface of one cell type but not the other. This invention also provides a method for preparing a hybridoma cell line which ... 07/28/05 - 20050163708 - Chimeric antibody with specificity to human b cell surface antigen A chimeric antibody with human constant region and murine variable region, having specificity to a 35 kDA polypeptide (Bp35(CD20)) expressed on the surface of human B cells, methods of production, and uses. ... 07/28/05 - 20050163707 - Cancer treatment The invention relates to a therapeutic system comprising (i) a radiolabelled antibody, which binds selectively to polymorphic epithelial mucin (PEM) such as the monoclonal antibody HMFG-1, and (ii) a chemotherapeutic agent, such as Taxotere®. The radiolabelled antibody and chemotherapeutic agent are administered in combination with one another to produce a ... 07/21/05 - 20050158242 - Novel method of diagnosing, monitoring, staging, imaging and treating various cancers The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer. ... 07/21/05 - 20050158241 - Novel method of diagnosing, monitoring, staging, imaging and treating various cancers The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating selected cancers including gynecologic cancers such as breast, ovarian, uterine and endometrial cancer and lung cancer. ... 07/14/05 - 20050152837 - Novel method of diagnosing, monitoring, staging, imaging and treating cancer The present invention provides new methods for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating cancer. ... 07/14/05 - 20050152836 - Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof The invention identifies genes whose expression is upregulated or downregulated following mechanical offloading in subjects with heart failure. The invention provides compositions comprising a targeting agent conjugated to a functional moiety, wherein the targeting agent selectively binds to a polypeptide encoded by one of these genes. The functional moiety can ... 07/07/05 - 20050147556 - Method of diagnosing, monitoring, staging, imaging and treating prostate cancer The present invention provides a new method for detecting, diagnosing, monitoring, staging, prognosticating, imaging and treating prostate cancer. ... 07/07/05 - 20050147555 - Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same Methods for the preparation of multivalent constructs for therapeutic and diagnostic applications are provided. More specifically, novel methods for preparing multivalent constructs comprising the formula A-B-C-D-E-B′-F for therapeutic and diagnostic applications are provided which use a novel linker D comprising, in various embodiments, a dicarboxylic acid derivative such as, e.g., ... 06/30/05 - 20050142062 - Novel method of diagnosing and treating gliomas The present invention provides a recombinant toxin and monoclonal antibody which specifically binds to glial-derived or meningioma-derived tumor cells. Also provided are various methods of screening for malignant gliomas and meningiomas. Further provided are methods of treating malignant gliomas, including glioblastoma multiforme and astrocytomas. ... 06/30/05 - 20050142061 - Radiofluorination methods may be reacted with an activated peptide as a means for 18F-labelling. ... // - 18F—(CH2)p—SH (V) - ... // - 18F—(CH2CH2O)n—(CH2)m—SH (IV) - ... 06/23/05 - 20050136004 - Anti-il-20 antibodies and binding partners and methods of using in inflammation The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such ... 06/16/05 - 20050129616 - Antibodies that immunospecifically bind to trail receptors The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these ... 06/16/05 - 20050129615 - Non-invasive system for detecting skin cancer The invention concerns methods and compositions for the diagnosis of cancer. The invention further concerns diagnostic patches which may be contacted topically with an externally accessible tissue surface for the purpose of detecting the presence or absence of cancer. ... 06/16/05 - 20050129614 - Antibodies that specifically bind to tl5 The present invention relates to antibodies and related molecules that specifically bind to TL5. Such antibodies have uses, for example, in the prevention and treatment of cancer as well as immune system diseases and disorders including autoimmune disease, rheumatoid arthritis, graft rejection, graft vs. host disease, and lymphadenopathy. The invention ... 06/09/05 - 20050123476 - Imaging the activity of extracellular protease in cells using mutant anthrax toxin protective antigens that are cleaved by specific extracellular proteases This invention pertains to methods for imaging the activity of extracellular proteases in cells using the anthrax binary toxin-system to target cells expressing extracellular proteases with mutant anthrax toxin protective antigens (μPrAg) that bind to receptors on the cells and are cleaved by a specific extracellular protease expressed by the ... 06/02/05 - 20050118099 - Thiol-mediated drug attachment to targeting peptides Compositions and methods for thiol-specific attachment of therapeutic and diagnostic agents to somatostatin and other targeting peptides. ... ### FreshPatents.com Support |